住院患者药物性肝损伤病因分析及熊去氧胆酸协同治疗疗效观察

doi:10.3969/j.issn.1672-5069.2015.01.009

摘要/Abstract

摘要： 目的观察熊去氧胆酸协同治疗药物性肝损伤（DILI）患者的临床疗效,分析我院引起DILI的药物种类及其发生比例。方法纳入我院200例药物性肝损伤患者,分析引起DILI的药物种类。将患者分成两组,对照组给予异甘草酸镁、谷胱甘肽和多烯磷酯酰胆碱中的1~3种药物治疗,对伴有高胆红素血症者加用腺苷蛋氨酸;治疗组在对照组治疗的基础上,加用熊去氧胆酸,两组疗程均为4 w,观察治疗后肝功能变化和临床疗效。结果本组引起DILI的首位药物是免疫抑制剂（34.0%）,其次为中药（28.5%）,其后依次为抗生素（13.0%）、抗结核药物（7.5%）、抗肿瘤化疗药（7.5%）和解热镇痛药（4.5%）;治疗组在肝功能改善方面明显优于对照组（P<0.01）,尽管两组患者肝功能均有明显改善。结论引起我院住院患者DILI的最常见的药物为免疫抑制剂,可能与我院开展器官移植较多有关。熊去氧胆酸在甘草酸制剂等的基础上可以较快地改善DILI患者肝功能。

关键词: 药物性肝损伤, 诱发药物, 熊去氧胆酸, 中药

Abstract: Objective To investigate the common agents related to drug-induced liver injury（DILI） in our hospitalized patients and to observe the clinical efficacy of ursodeoxycholic acid in treatment of patients with DILI. Methods Two hundred patients with DILI were recruited in this study and the common agents were analyzed. The patients were divided into two groups. Patients in control group received magnesium isoglycyrrhizinate, glutathione and polyene phosphatidylcholine（one,two,and all or any combination of them） for four weeks. Ademetionine was given when hyperbilirubinemia appeared. The patients in observation group received additionally ursodeoxycholic acid for four weeks at the base treatment in the control. Results The leading agents in our patients with DILI were immunosuppressive agents（34.0%）,followed by traditional Chinese medicin（28.5%）,and other common agents were antibacterial（13.0%）,antitubercular agents（7.5%）, chemotherapeutics（7.5%）,and antipyretic analgesics（4.5%）. Liver function improved in both groups after four week treatment,while the efficacy was superior in ursodeoxycholic acid-treated patients（P<0.01）. Conclusion Immunosuppressive agents are the main causes of DILI in our hospitalized patients, and the ursodeoxycholic acid could improve the efficacy of basic treatment such as glycyrrhizin in patients with DILI.

Key words: Drug-induced liver injury, Common agents, Ursodeoxycholic acid, Traditional Chinese medicine

施慧, 魏娟, 王震凯, 王少东, 杨妙芳, 路又可, 刘炯, 汪芳裕. 住院患者药物性肝损伤病因分析及熊去氧胆酸协同治疗疗效观察[J]. 实用肝脏病杂志, 2015, 18(1): 34-37.

Shi Hui, Wei Juan, Wang Zhenkai, et al. Common agents in patients with drug-induced liver injury and observation of therapeutic efficacy of ursodeoxycholic acid[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 34-37.

参考文献

[1] Stephens C,Lucena MI,Andrade RJ. Genetic variations in drug-induced liver injury（DILI）:resolving the puzzle. Front Genet,2012,16（11）:253-253.
[2] Nathwani RA,Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis,2006,10（2）:207-217.
[3] Devarbhavi H,Dierkhising R,Kremers WK,et al. Single-center experience with drug-induced liver injury from India:causes,outcome,prognosis,and predictors of mortality. Am J Gastroenterol,2010,105:2396-2404.
[4] Au JS,Navarro VJ,Rossi S. Review article: Drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther,2011,34:11-20.
[5] 中华消化专业委员会. 急性药物性肝损伤诊治建议（草案）. 中华消化杂志,2007,27（11）:765-767.
[6] Bagheri H,Michel F,Lapeyre-Mestre M,et al. Detection and incidence of drug-induced liver injuries in hospital:a prospective analysis from laboratory signals. Br J Clin Pharmacol,2000,50:479-484.
[7] Aithal GP,Watkins PB,Andrade RJ,et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther,2011,89:806-815.
[8] Au JS,Navarro VJ,Rossi S. Review article:drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther,2011,34:11-20.
[9] 李晨,辛绍杰,游绍莉. 中草药致肝损害研究进展. 实用肝脏病杂志,2013,16（6）:278-281.
[10] García-Cortés M,Lucena MI,Pachkoria K,et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug induced liver injury. Aliment Pharmacol Ther,2008,27:780-789.
[11] Takikawa H,Murata Y,Horiike N,et al. Drug induced liver injury in Japan:An analysis of 1676 cases between 1997 and 2006. Hepatol Res,2009,39: 427-431.
[12] 魏傲,石小枫. 药物性肝损害344例临床分析. 现代医药卫生,2010,26:3528-3530.
[13] Xu HM,Chen Y,Xu J,et al. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol,2012,18（41）:5972-5978.
[14] 中华医学会消化病分会肝胆疾病协作组.全国多中心急性药物性肝损伤住院病例调研分析. 中华消化杂志,2007,27（7）:439-442.
[15] 苏尊玮,廖宗琳. 中药与西药所致药物性肝损伤的临床对比分析. 实用肝脏病杂志,2009,12（2）:137-138.
[16] Fontana RJ,Watkins PB,Bonkovsky HL,et al. Drug-induced liver injury network（DILIN） prospective study:rationale,design and conduct. Drug Saf,2009,32:55-68.
[17] Fontana RJ,Seeff LB,Andrade RJ,et al. Standardization of nomenclature and causality assessment in drug-induced liver injury:summary of a clinical research workshop. Hepatology,2010,52:730-742.
[18] Kato H,Horita N,Miyazawa N,et al. Risk factors for liver injury with an elevated serum bilirubin concentration caused by antituberculous drugs. Intern Med,2013,52（19）:2209-22014.
[19] 滕光菊,孙颖,常彬霞,等. 418例药物性肝损害临床特征及预后分析. 肝脏,2013,18:11-14.
[20] Wree A,Dechêne A,Herzer K,et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion,2011,84（1）:54-59.
[21] 周健,刘黎,黄丽雯,等. 牛磺熊去氧胆酸治疗非酒精性脂肪肝疗效观察. 实用肝脏病杂志,2014,17（1）:80-81.
[22] Anwar S,Jawad H,Sawsan S. A study of the effect of Nigella sativa （Black seeds） in isoniazid （INH）-induced hepatotoxicity in rabbits. Indian J Pharmacol,2012,44（6）:678-682.
[23] Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov,2005,4:489-499.